A Phase 2 interventional study of AU-011 and SCS Microinjector in Eye Cancer and Primary Cancer, sponsored by Aura Biosciences. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Aura Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Eye Neoplasms with a site in United States — 4 open to participants now, 8 under way, 1 of them phase 3. Eye Neoplasms · United States.
Among the 22 studies in Eye Neoplasms with a site in United States, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 2, and was the 20th registered.
32 studies on the registry are indexed under Eye Neoplasms; 4 are open to participants now.
Browse Eye Neoplasms studies →4 of the 22 studies in Eye Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Novelwise Pharmaceutical Corporation · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 4 wk+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Eye Neoplasms studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 2
First in 2000; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 36 across 19 interventional studies indexed under Eye Neoplasms.
Median enrollment 40 across the 15 interventional studies, 33 across the 5 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
Aura Biosciences is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Aura Biosciences has 5 studies filed under Eye Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Eye Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06007690Phase 3Aura BiosciencesA Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | 2027-11-15 |
| NCT06643884Aura BiosciencesSuprachoroidal Administration in Subjects With Metastases to the Choroid | 2026-11-30 |
| NCT01653080University of CincinnatiMRI in Diagnosing Solid Tumors of the Eye and Orbit | 2026-12-31 |
| NCT03713268Duke UniversityIntraoperative OCT Guidance of Intraocular Surgery II | 2026-12-31 |
| NCT05415072Novartis PharmaceuticalsA Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies in Eye Neoplasms with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
This is an open-label, dose escalation trial designed to assess safety and tolerability of 4 dose strengths and 1-2 cycles of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
The criteria were revised on the registry on Oct 8, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 Cycle AU-011 with a dose of 80 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
1 Cycle AU-011 with a dose of 140 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
1 Cycle AU-011 with a dose of 200 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
2 Cycles AU-011 with a dose of 200 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
Subjects that meet trial inclusion, but do not meet criteria for enrollment into the bel-sar treatment cohorts, may be enrolled in this cohort. The observational cohort will not receive bel-sar treatment.
1 Cycle AU-011 with a dose of 40 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
2 Cycles AU-011 with a dose of 40 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
AU-011 Via Suprachoroidal Administration with laser treatment
Suprachoroidal Injection Device
Laser Administration
Change from baseline in choroidal tumor thickness on B-scan ultrasonography (B-scan) 4 weeks after completion of treatment.
B-Scan Ultrasonography
Time frame: 4 weeks after completion of treatment
Change from baseline in choroidal tumor largest basal diameter (LBD) on fundus photos 4 weeks after completion of treatment.
Fundus photos
Time frame: 4 weeks after completion of treatment
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belzupacap sarotalocan
Aura Biosciences